
Opinion|Videos|January 31, 2025
CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors
Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.
Advertisement
Episodes in this series

Provide an overview of the current landscape of first-line treatment options for CLL. What role do BTK inhibitors have in this landscape?
What continued role does ibrutinib have in the current CLL treatment landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
2
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
3
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
4
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
5